Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-C: Lumasiran in Advanced PH1
NCT04152200Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- May 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 11
01
Overview
A Phase 3 trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1), sponsored by Alnylam Pharmaceuticals. Started Jan 2020; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT04152200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152200.